Erratum: A Novel Small Molecule Aurora Kinase Inhibitor Attenuates Breast Tumor Initiating Cells and Overcomes Drug Resistance (Molecular Cancer Therapeutics (2014) 13 (1991-2003) DOI: 10.1158/1535-7163.MCT-13-1029);A novel small molecule Aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance

Molecular Cancer Therapeutics

Volumn 13, Issue 8, 2014, Pages 1991-2003

  Zheng, Fei Meng ^a,b,d   Long, Zi Jie ^c   Hou, Zhi Jie ^d   Luo, Yu ^c   Xu, Ling Zhi ^d   Xia, Jiang Long ^d   Lai, Xiao Ju ^a,b   Liu, Ji Wei ^d   Wang, Xi ^a,b   Kamran, Muhammad ^d   Yan, Min ^a,b   Shao, Shu Juan ^b   Lam, Eric W F ^e   Wang, Shao Wu ^d   Lu, Gui ^c   Liu, Quentin ^a,b,c,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Institute of Cancer Stem Cell First Affiliated Hospital Collaborative Innovation Center of Oncology   (China)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AKI 603; AURORA A KINASE; AURORA KINASE INHIBITOR; BETA CATENIN; CD24 ANTIGEN; EPIRUBICIN; HERMES ANTIGEN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; AKI603; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL RENEWAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR INITIATING CELL; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STEM CELL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; MCF 7 CELL LINE; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASE A; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIRUBICIN; FEMALE; HUMANS; MCF-7 CELLS; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SPHEROIDS, CELLULAR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905669100     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-22-0150     Document Type: Erratum

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013;2:3.
3. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532.
4. Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009;69:2996-3003.
5. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 2007;21:2283-7. (Pubitemid 47443334)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
8. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-7.
9. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
10. Neumeister V, Rimm D. Is ALDH1 a good method for definition of breast cancer stem cells? Breast Cancer Res Treat 2010;123:109-11.
11. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54. (Pubitemid 37411723)
12. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 2005;5:42 -50.
13. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927- 36.
14. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004;36:55-62. (Pubitemid 38056208)
15. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004;279:52175-82. (Pubitemid 39656591)
16. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004;279:19643-8. (Pubitemid 38623401)
17. Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 2012;21:196-211.
18. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stemcells. Cancer Res 2010;70:4655-65.
19. Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011;10:1046-58.
20. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70. (Pubitemid 36583168)
21. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517-24. (Pubitemid 24330215)
22. Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol 2011;731:421-34.
23. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 1988;2:886-92.
24. Ma X, Cai Y, He D, Zou C, Zhang P, Lo CY, et al. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci U S A 2012;109:16282-7.
25. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009;4:e6146.
26. Wagner RT, Xu X, Yi F, Merrill BJ, Cooney AJ. Canonical Wnt/beta-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. Stem Cells 2010;28:1794-804.
27. Anton R, Kestler HA, Kuhl M. Beta-catenin signaling contributes to stemness and regulates early differentiation in murine embryonic stem cells. FEBS Lett 2007;581:5247-54. (Pubitemid 350018750)
28. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20.
29. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. (Pubitemid 44233629)
30. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-8. (Pubitemid 46386404)
31. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012;31:4898-911.
32. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012;31:1354-65.
33. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates selfrenewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 2012;56:1004-14.
34. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999;5:2588-95. (Pubitemid 29437346)
35. Yang L, Zhang X, Zhang M, Zhang J, Sheng Y, Sun X, et al. Increased Nanog expression promotes tumor development and Cisplatin resistance in human esophageal cancer cells. Cell Physiol Biochem 2012;30:943-52.
36. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9&z.ast;-mediated suppression of SOX2. Cancer Res 2011;71:3410-21.
37. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 2002;22:874-85. (Pubitemid 34053065)
38. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002;21:483-92. (Pubitemid 34174030)
39. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-88. (Pubitemid 41486361)
40. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92. (Pubitemid 40227997)
41. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, Gastaut JA, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60:4403-11. (Pubitemid 32103618)
42. Zhang L, Yang S, He YJ, Shao HY, Wang L, Chen H, et al. Fluorouracil selectively enriches stem-like leukemic cells in a leukemic cell line. Int J Biol Sci 2010;6:419-27.
43. Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-9. (Pubitemid 29469430)
44. Berdnik D, Knoblich JA. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002;12:640-7. (Pubitemid 34315847)
45. Lee CY, Andersen RO, Cabernard C, Manning L, Tran KD, Lanskey MJ, et al. Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. Genes Dev 2006;20:3464-74. (Pubitemid 44969163)
46. Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 2012;11:179-94.
47. Cheng C, Liu ZG, Zhang H, Xie JD, Chen XG, Zhao XQ, et al. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. Mol Pharm 2012;9:1971-82.